-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Editor’s note iNature is China’s largest academic public account.
It is jointly created by a team of doctors from Tsinghua University, Harvard University, Chinese Academy of Sciences and other units.
The iNature talent public account is now launched, focusing on talent recruitment, academic progress, scientific research information, interested parties can Long press or scan the QR code below to follow us
.
Recent studies by iNature have revealed the significant imbalance of m6A levels in peripheral blood of several cancer types and their value in diagnosis
.
Nevertheless, based on the viewpoint of m6A modification, biomarkers for accurate screening of multiple cancer types have not yet been established
.
On December 20, 2021, Chen Jinhong’s team from Fudan University published a research paper titled "m6A target microRNAs in serum for cancer detection" online in Molecular Cancer (IF=27), which aims to develop a miRNA based on m6A targeting The serological diagnostic features of the drug are used for large-scale cancer detection
.
A total of 14,965 serum samples from 12 cancer types were included
.
Based on the training cohort (n=7299), the m6A-miRNAs feature was developed using the support vector machine algorithm for cancer detection
.
The characteristics of m6A-miRNAs showed high accuracy, and the area under the curve (AUC) in the training, internal validation and external validation cohorts reached 0.
979, 0.
976, and 0.
936, respectively
.
In the performance of distinguishing cancer types, the characteristics of m6A-miRNAs showed excellent sensitivity in each cancer type, and showed satisfactory AUC in identifying lung cancer, gastric cancer and hepatocellular carcinoma
.
In addition, the diagnostic performance of m6A-miRNA is not affected by gender, age, and benign diseases
.
In conclusion, this study reveals the value of serum circulating m6A miRNA in cancer detection, and provides a new direction and strategy for the development of new biomarkers with high precision, low cost and low invasiveness for large-scale cancer screening
.
Most new cancer cases are usually found in the late stage, which makes the patient lose the best chance of treatment, leading to a poor prognosis
.
Early diagnosis of cancer is of great significance for reducing mortality, prolonging patient survival, and reducing social burden
.
Due to the disadvantages of existing cancer screening methods such as high cost, strong invasiveness, poor compliance, and low accuracy, large-scale cancer screening based on existing methods is neither feasible nor cost-effective
.
Considering that early diagnosis of cancer can significantly prolong the survival of patients, there is an urgent need to develop a more effective and less invasive new biomarker for large-scale cancer screening
.
N6-methyladenosine (m6A) modification is the most common modification in mRNA, and it is also widely present in mRNA, miRNA and lncRNA
.
The imbalance of m6A modification level is closely related to the occurrence and development of tumors
.
Recent studies have revealed significant dysregulation of m6A levels in peripheral blood of several cancer types and their value in diagnosis
.
The level of m6A in peripheral blood of patients with gastric cancer was significantly up-regulated compared with healthy controls, and increased with the progression and metastasis of gastric cancer
.
The AUC used to evaluate the diagnostic performance of m6A in gastric cancer was 0.
929, which was significantly greater than CEA and CA19-9
.
The level of m6A in peripheral blood of breast cancer patients is also significantly up-regulated, and is closely related to staging, and its diagnostic value is much higher than CEA and CA153
.
Leukocyte m6A level is a potential non-invasive screening, monitoring and diagnostic biomarker for non-small cell lung cancer
.
Existing evidence suggests that the m6A tag, as a key post-transcriptional modification, promotes the initiation of miRNA biogenesis, such as the promotion of primary microRNA processing
.
It has been confirmed that miRNA dysregulation caused by m6A plays an important role in tumor metastasis and progression
.
Circulating miRNAs in serum have high stability, and their expression is less affected by long-term storage at room temperature and freezing and thawing
.
The above results indicate that the development of new diagnostic biomarkers based on the m6A target miRNA in peripheral blood may be a potential strategy for large-scale cancer screening
.
In this study, 14,965 serum samples containing 12 cancer types were included, aiming to develop a serological diagnostic feature based on m6A-targeted miRNA for large-scale cancer detection
.
The characteristics of m6A-miRNAs showed high accuracy, and the area under the curve (AUC) in the training, internal validation and external validation cohorts reached 0.
979, 0.
976, and 0.
936, respectively
.
In addition, in terms of the performance of distinguishing cancer types, the characteristics of m6A-miRNAs showed excellent sensitivity in each cancer type, and showed satisfactory AUC in identifying lung, gastric, and hepatocellular carcinoma
.
The identification of candidate m6A-targeted miRNAs in serum (the figure is derived from Molecular Cancer) The diagnostic performance of m6A-miRNAs is also not affected by gender, age, and benign diseases
.
In conclusion, this study reveals the value of serum circulating m6A miRNA in cancer detection, and provides a new direction and strategy for the development of new biomarkers with high precision, low cost and low invasiveness for large-scale cancer screening , Such as RNA modification
.
Reference message: https://molecular-cancer.
biomedcentral.
com/articles/10.
1186/s12943-021-01477-6
It is jointly created by a team of doctors from Tsinghua University, Harvard University, Chinese Academy of Sciences and other units.
The iNature talent public account is now launched, focusing on talent recruitment, academic progress, scientific research information, interested parties can Long press or scan the QR code below to follow us
.
Recent studies by iNature have revealed the significant imbalance of m6A levels in peripheral blood of several cancer types and their value in diagnosis
.
Nevertheless, based on the viewpoint of m6A modification, biomarkers for accurate screening of multiple cancer types have not yet been established
.
On December 20, 2021, Chen Jinhong’s team from Fudan University published a research paper titled "m6A target microRNAs in serum for cancer detection" online in Molecular Cancer (IF=27), which aims to develop a miRNA based on m6A targeting The serological diagnostic features of the drug are used for large-scale cancer detection
.
A total of 14,965 serum samples from 12 cancer types were included
.
Based on the training cohort (n=7299), the m6A-miRNAs feature was developed using the support vector machine algorithm for cancer detection
.
The characteristics of m6A-miRNAs showed high accuracy, and the area under the curve (AUC) in the training, internal validation and external validation cohorts reached 0.
979, 0.
976, and 0.
936, respectively
.
In the performance of distinguishing cancer types, the characteristics of m6A-miRNAs showed excellent sensitivity in each cancer type, and showed satisfactory AUC in identifying lung cancer, gastric cancer and hepatocellular carcinoma
.
In addition, the diagnostic performance of m6A-miRNA is not affected by gender, age, and benign diseases
.
In conclusion, this study reveals the value of serum circulating m6A miRNA in cancer detection, and provides a new direction and strategy for the development of new biomarkers with high precision, low cost and low invasiveness for large-scale cancer screening
.
Most new cancer cases are usually found in the late stage, which makes the patient lose the best chance of treatment, leading to a poor prognosis
.
Early diagnosis of cancer is of great significance for reducing mortality, prolonging patient survival, and reducing social burden
.
Due to the disadvantages of existing cancer screening methods such as high cost, strong invasiveness, poor compliance, and low accuracy, large-scale cancer screening based on existing methods is neither feasible nor cost-effective
.
Considering that early diagnosis of cancer can significantly prolong the survival of patients, there is an urgent need to develop a more effective and less invasive new biomarker for large-scale cancer screening
.
N6-methyladenosine (m6A) modification is the most common modification in mRNA, and it is also widely present in mRNA, miRNA and lncRNA
.
The imbalance of m6A modification level is closely related to the occurrence and development of tumors
.
Recent studies have revealed significant dysregulation of m6A levels in peripheral blood of several cancer types and their value in diagnosis
.
The level of m6A in peripheral blood of patients with gastric cancer was significantly up-regulated compared with healthy controls, and increased with the progression and metastasis of gastric cancer
.
The AUC used to evaluate the diagnostic performance of m6A in gastric cancer was 0.
929, which was significantly greater than CEA and CA19-9
.
The level of m6A in peripheral blood of breast cancer patients is also significantly up-regulated, and is closely related to staging, and its diagnostic value is much higher than CEA and CA153
.
Leukocyte m6A level is a potential non-invasive screening, monitoring and diagnostic biomarker for non-small cell lung cancer
.
Existing evidence suggests that the m6A tag, as a key post-transcriptional modification, promotes the initiation of miRNA biogenesis, such as the promotion of primary microRNA processing
.
It has been confirmed that miRNA dysregulation caused by m6A plays an important role in tumor metastasis and progression
.
Circulating miRNAs in serum have high stability, and their expression is less affected by long-term storage at room temperature and freezing and thawing
.
The above results indicate that the development of new diagnostic biomarkers based on the m6A target miRNA in peripheral blood may be a potential strategy for large-scale cancer screening
.
In this study, 14,965 serum samples containing 12 cancer types were included, aiming to develop a serological diagnostic feature based on m6A-targeted miRNA for large-scale cancer detection
.
The characteristics of m6A-miRNAs showed high accuracy, and the area under the curve (AUC) in the training, internal validation and external validation cohorts reached 0.
979, 0.
976, and 0.
936, respectively
.
In addition, in terms of the performance of distinguishing cancer types, the characteristics of m6A-miRNAs showed excellent sensitivity in each cancer type, and showed satisfactory AUC in identifying lung, gastric, and hepatocellular carcinoma
.
The identification of candidate m6A-targeted miRNAs in serum (the figure is derived from Molecular Cancer) The diagnostic performance of m6A-miRNAs is also not affected by gender, age, and benign diseases
.
In conclusion, this study reveals the value of serum circulating m6A miRNA in cancer detection, and provides a new direction and strategy for the development of new biomarkers with high precision, low cost and low invasiveness for large-scale cancer screening , Such as RNA modification
.
Reference message: https://molecular-cancer.
biomedcentral.
com/articles/10.
1186/s12943-021-01477-6
